MergerAug 13, 2026, 04:10 PM
VYNE Therapeutics Completes Merger with Yarrow Bioscience
AI Summary
VYNE Therapeutics Inc. completed its merger with Yarrow Bioscience, Inc. on July 27, 2026, subsequently changing its name to Yarrow Bioscience, Inc. and focusing on Yarrow's clinical-stage biotechnology business. The company also effected a 1-for-50 reverse stock split and declared a $17.3 million special cash dividend. For the six months ended June 30, 2026, the company reported a net loss of $(6.6) million, with cash and cash equivalents at $22.9 million.
Key Highlights
- Completed merger with Yarrow Bioscience on July 27, 2026.
- Company renamed Yarrow Bioscience, Inc. post-merger.
- Effected a 1-for-50 reverse stock split on July 24, 2026.
- Declared a $17.3 million special cash dividend on July 10, 2026.
- Cash and cash equivalents totaled $22.9 million as of June 30, 2026.
- Net loss for H1 2026 was $(6.6) million, down from $(14.4) million in H1 2025.
- R&D expenses decreased to $1.6 million for H1 2026 from $11.0 million in H1 2025.
- Regained Nasdaq minimum bid price compliance on August 10, 2026.
Price Impact
More from VYNE